Meeting
2016 Gastrointestinal Cancers Symposium
Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis.
Authors
Lorenzo Antonuzzo
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Lorenzo Antonuzzo , Giuseppe Aprile , Sandro Barni , Evaristo Maiello , Gianluca Masi , Fausto Petrelli , Luca Porcu , Mario Scartozzi , Valter Torri , Carmine Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 705)
DOI
10.1200/jco.2016.34.4_suppl.705
Abstract #
705
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
First Author: Julien Taieb
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2020 Gastrointestinal Cancers Symposium
Safety and efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab in clinical practice for patients with chemorefractory metastatic colorectal cancer: A retrospective comparative study.
First Author: Yoshinori Kagawa